Navigation Links
Secretary Reinforces VA's Commitment to Research Safety and Veteran Focus
Date:7/9/2008

, Chantix, is in fact considered to be the most effective medication available for smoking cessation with six million prescriptions written.

Peake noted any veterans receiving Chantix in the study or anywhere in the VA had been put on the drug by their doctors as an individual doctor-patient decision, with continued monitoring the health status. As information within the VA and by the FDA suggested potential psychological side effects were being seen in some patients taking Chantix, Clinical providers were notified promptly. Not only were letters sent by researchers to members of the study, but, additionally, a letter has been sent to every veteran prescribed Chantix by the VA discussing possible side-effects, encouraging them to contact their provider immediately if they experience side effects and assuring them that the VA will help them find another way to quit smoking if they are concerned about Chantix or are having side effects.

More than 60 FDA approved drugs could have adverse effects that may include "suicidal ideation and suicidal behavior," Peake said. "If VA were to withhold these medications from our patients with mental health issues, we would have great difficulty treating them. Weighing the risk -- and all drugs have risks -- against the benefit with the best information available is what the doctor and patient do as a drug is prescribed."

The Secretary also addressed allegations implying VA research is somehow compromised by outside entities such as drug companies and universities calling it ridiculous. The smoking cessation study was solely funded by the VA, with no outside funding. VA research is approved by VA's Office of Research and Development and does not require approval from the Secretary, including this smoking cessation study. The scientific review and human subjects protection processes ensure that VA research addresses specifically and only the purpose of the study.

Peake has also directed four internal inves
'/>"/>

SOURCE U.S. Department of Veterans Affairs
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Health Secretary Reminds Kids to Stop Germs - Wash Hands
2. Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
3. GeoVax Secures $10 Million Financing Commitment
4. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
5. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
6. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
7. Pediatric Researchers Find Possible Master Switch Gene in Juvenile Arthritis
8. Childrens Brain Tumor Foundations Tissue Bank Consortium May Solve Dire Problem in Pediatric Cancer Research
9. Small Business Innovation Research Program Awards Grant to Biomoda
10. Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimers Therapeutic Antibody
11. New Research Just Released: Women Can Now Safely Postpone Motherhood Until Time Is Right
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)...nking polyphenol-rich 100% Concord grape,juice was...ntake or body,weight, CONCORD, Mass., Oct. 6 /PRN...-rich Concord grape juice did not cause significan...appetite and was shown to reduce waist,circumferen...ual Meeting of,the American College of Nutrition i...
(Date:10/3/2008)...ase Inhibitors for Cancer Treatments, INDIANAPOLI...stCall/ --,Eli Lilly and Company (NYSE: LLY ) and...ay announced that the two companies have entered,i...ent related to,Deciphera,s preclinical B-Raf kinas...ology therapeutics., The collaboration will apply...
(Date:10/2/2008)...RNewswire/ -- Calabar AB announced today,that thei... mouth"),patients has been initiated. Specifically...s between the ages of 20 to 75. The objective of t...ucceeding Phase III efficacy,study., Xalieve(TM) ...hysostigmine. It is administered locally in the mo...
(Date:10/1/2008)...tial of Amylin,s integrated neurohormonal ... DIEGO, Oct. 1 /- Amylin Ph...ed that new data for its pipeline obesity,candidat... Meeting of The,Obesity Society in Phoenix October...of the largest and most comprehensive scientific c...
Breaking Medicine Technology:Concord Grape Juice Has No Significant Impact on Body Weight 2Concord Grape Juice Has No Significant Impact on Body Weight 3Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement 2Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement 3Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients 2Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 2Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 4Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 5Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 6Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 7Docs Issue Guideline on Screening for Osteoporosis in Men 18604 1Docs Issue Guideline on Screening for Osteoporosis in Men 18604 2iCAD Reports First Quarter 2008 Financial Results 5164 1iCAD Reports First Quarter 2008 Financial Results 5164 2iCAD Reports First Quarter 2008 Financial Results 5164 3iCAD Reports First Quarter 2008 Financial Results 5164 4iCAD Reports First Quarter 2008 Financial Results 5164 5iCAD Reports First Quarter 2008 Financial Results 5164 6iCAD Reports First Quarter 2008 Financial Results 5164 7iCAD Reports First Quarter 2008 Financial Results 5164 8iCAD Reports First Quarter 2008 Financial Results 5164 9Pharm Olam Finds VoIP Solution in Taridium LLC 5160 1Pharm Olam Finds VoIP Solution in Taridium LLC 5160 2Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 1Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 2Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 3Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 4Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 5Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 6Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 7Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 8Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 9
...ING, N.J.--(BUSINESS WIRE)--Apr 19, 2007 - Antares...ts from a recently completed,site application stud...TD(TM) transdermal gel, was absorbed on a bioequiv...ee different skin site,locations., The study was a...lication site pharmacokinetic study. The trial enr...
...Unique Viral Kinetics Profile, LAUSANNE, Switzerla...p (Debiopharm), a global independent biopharmaceut...s medical conditions,presented additional results...ilin (Cyp) inhibitor Debio 025 in HIV/HCV (hepatit...esented at the 42nd,Annual Meeting of the European...
Other Medicine Technology:Antares Pharma Announces Positive Results from Application Site,Study for Anturol 2Antares Pharma Announces Positive Results from Application Site,Study for Anturol 3Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment,of HCV 2Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment,of HCV 3Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment,of HCV 4
(Date:10/6/2008)... Lutherville-based civil litigation and criminal...on Co. after jury awarded $3.2 million to plaintif...herville, Maryland ((Lexis Nexis) October 6, 2008 ...l.com/ [Miller, Murtha & Psoras] have successf...lf of a Maryland welder who was awarded more than ...
(Date:10/5/2008)...considerable disparities in survival related to ra...ead and neck cancer. Published in the November 15,...f the American Cancer Society, the study indicates...tment could improve outcomes for these cancers amo... studies have examined disparities in cancer survi...
(Date:10/5/2008)...ospitalized kids with painful ailments from broken...killing drugs known as opiates. The medications bl...nstipation, for instance, is one side effect that ...spital stay. , "No parent wants their child in t...Sharek, MD, MPH, medical director for quality mana...
(Date:10/5/2008)...tle exercise goes a long way toward helping severe... and complete important daily tasks, according to ..., In a pre-program assessment where patients repo...per week, individuals who were more active reporte...ed improvements in their ability to perform daily ...
Breaking Medicine News(10 mins):Health News:Miller, Murtha & Psoras Secures Multimillion-Dollar Settlement for Victim of Industrial Accident at Bethlehem Steel 2Health News:News from Cancer: Disparities in head and neck cancer patients 2Health News:Major study of opiate use in children's hospitals provides simple steps to alleviate harm 2Health News:Major study of opiate use in children's hospitals provides simple steps to alleviate harm 3Health News:A little exercise goes a long way for severely obese 2
...s from the Harvard School of Public Health now rev...n health risks. They have found that women who car...isk of coronary heart disease. The findings were r... which had collected data on caregiving and corona...
...ming in laboratory studies that one of the substan...hives--may inhibit the development of tooth decay...., found that propolis// considerably reduces denta...r of glucosyltransferase (Gtf) enzymes, enzymes th...
...fferent specialties, recently joined hands to demo...er patients. Dr. Peter Costantino, an otolaryngolo...n fatal tumor in Angela Carrozza’s nasal cavity an...iety of Clinical Oncology, nearly 38,000 cases of ...
...illion people go to the Emergency Room(ER) with ch... Most receive an ECG and other standard tests to d...r serious heart problems. However, ECGs can be com... place. ECGs are also sometimes unable to identify...
Other Medicine News:
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
Medicine Products: